Sugar-Binding Proteins Prevent SARS-CoV-2 Variants from Invading

  • Author: ChemistryViews
  • Published: 18 August 2021
  • Copyright: Wiley-VCH GmbH
thumbnail image: Sugar-Binding Proteins Prevent SARS-CoV-2 Variants from Invading

The SARS-CoV-2 virus uses a glycosylation mechanism at specific sites on the spike (S) protein to form a sugar coat that hides the antigenic protein from the host immune response. New SARS-CoV-2 variants are constantly emerging, but the 22 N-glycan sites of the spike remain highly conserved among SARS-CoV-2 variants. This opens an avenue for robust therapeutic interventions.


Josef M. Penninger, IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, and University of British Columbia (UBC), Vancouver, Canada, and colleagues have prepared and used a library of over 140 mammalian carbohydrate-binding proteins (lectins) to study critical sugar residues on the full-length trimeric Spike and the receptor-binding domain (RBD) of SARS-CoV-2. They found two lectins to bind strongly to the SARS-CoV-2 S protein: Clec4g and CD209c.

The researchers investigated which binding forces and how many bonds occur between the lectins and the S protein.
They found that the two lectins bind to the N-glycan site N343 of the S protein. Deletion of this glycosylation site makes the S protein unstable. Other groups have shown that viruses with mutated N343 are not infectious. Thus, the lectins bind to a glycan site that is essential for spike function and where a mutation is highly unlikely. Clec4g and CD209c also significantly reduced SARS-CoV-2 infections.

These data report the first extensive map and 3D structural modeling of lectin-Spike interactions and uncovers candidate receptors involved in Spike binding and SARS-CoV-2 infections. The capacity of CLEC4G and mCD209c to block SARS-CoV-2 viral entry holds promise for pan-variant therapeutic interventions, the researchers say.

The approach is similar to the mechanism of the drug candidate 'APN01' by Apeiron Biologics, Vienna, Austria, which is in advanced clinical trials. This involves a bioengineered human ACE2 that also binds to the spike protein. When the S protein is occupied by the drug, access to the cell is blocked. The two naturally occurring mammalian lectins can do just that, as well.


 

Also of Interest

 

 



 

Article Views: 2680

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH